Products for Research Use Only
RegisterLogin

Tomaralimab

CAT: 0804-HY-P99555-01Size: 1 mgDry Ice: YesHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P99555-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Tomaralimab (OPN-305) is a humanized anti-TLR2 IgG4 monoclonal antibody. Tomaralimab inhibits TLR2, MyD88, NLRP3, and reduces pro-inflammatory cytokine (IL-1β, IL-6, IL-8) production. Tomaralimab reduces tau pathology. Tomaralimab improves cognition, atopic dermatitis. Tomaralimab has anticancer effects on pancreatic ductal adenocarcinoma. Tomaralimab is being studied in myelodysplastic syndrome (MDS), atopic dermatitis, pancreatic ductal adenocarcinoma, Alzheimer's disease, and myocardial ischemia/reperfusion injury[1][2][3][4][5].
CAS Number
1449294-76-1
Product Name Alternative
OPN-305
UNSPSC
12352203
Target
Interleukin Related; MyD88; NOD-like Receptor (NLR) ; Tau Protein; Toll-like Receptor (TLR)
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation; Neuronal Signaling
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/tomaralimab.html
Purity
99.42
Solubility
10 mM in DMSO
Smiles
[Tomaralimab]
Molecular Weight
(145.32 kDa)
References & Citations
[1]GuillermoGarcia-ManeroMD, et al. A Clinical Study of Tomaralimab (OPN-305), a Toll-like Receptor 2 (TLR-2) Antibody, in Heavily Pre-Treated Transfusion Dependent Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received and Failed on Prior Hypomethylating Agent (HMA) Therapy. Blood, 2018, 798.|[2]Kim Y, et al. TLR2 immunotherapy suppresses neuroinflammation, tau spread, and memory loss in rTg4510 mice. Brain Behav Immun. 2024 Oct;121:291-302. |[3]Yeo H, et al. Therapeutic potential of a systemically applied humanized monoclonal antibody targeting Toll‑like receptor 2 in atopic‑dermatitis‑like skin lesions in a mouse model. Biomed Rep. 2024 Dec 30;22 (3) :41.|[4]Lundy J, et al. TLR2 activation promotes tumour growth and associates with patient survival and chemotherapy response in pancreatic ductal adenocarcinoma. Oncogene. 2021 Oct;40 (41) :6007-6022.|[5]Arslan F, et al. Treatment with OPN-305, a humanized anti-Toll-Like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs. Circ Cardiovasc Interv. 2012 Apr;5 (2) :279-87.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Isoform
IL-1; IL-6; IL-8; NLRP3

Alternative Products

CatalogName
GTR18153866-01Tomaralimab
GTR18337794-01Tomaralimab Antibody
592266Tomaralimab (TLR2, CD282)
KBI1695KRIBIOLISA™ Tomaralimab ELISA
WA3681Research Grade Tomaralimab
E55B0466Tomaralimab (Reference antibody)
A138787Tomaralimab Biosimilar (Monoclonal, IgG4)
A2333-01Tomaralimab (Anti-TLR2 / CD282)
ICH5932-25mgTomaralimab Biosimilar - Research Grade
GTR18697732-01Tomaralimab Chimeric Monoclonal Antibody

Popular Products